Cargando…
Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis
Cystic fibrosis (CF) is a life-limiting, multisystem disease characterized by thick viscous secretions leading to recurrent lung infections, bronchiectasis, and progressive deterioration in lung function. CF is caused by loss or dysfunction of the CF transmembrane conductance regulator (CFTR) protei...
Autores principales: | O’Reilly, Ruth, Elphick, Heather E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3770629/ https://www.ncbi.nlm.nih.gov/pubmed/24039402 http://dx.doi.org/10.2147/DDDT.S30345 |
Ejemplares similares
-
Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy
por: Connett, GJ
Publicado: (2019) -
Tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2019) -
Lumacaftor/ivacaftor for cystic fibrosis
Publicado: (2019) -
The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy
por: Lommatzsch, Sherstin T., et al.
Publicado: (2019) -
Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021)